K. Alberti, R. H. Robert, S. M. Grundy, P. Z. Zimmet, K. A. Clecman et al., Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, vol.120, issue.16, pp.1640-1645
DOI : 10.1161/CIRCULATIONAHA.109.192644

R. K. Simmons, K. G. Alberti, E. A. Gale, S. Colagiuri, J. Tuomilchto et al., Roglic The metabolic syndrome :; useful concept or clinical tool ?, pp.600-605

D. Lameira, S. Lejeune, and J. J. , Mourad Le syndrome métabolique : son épidémiologie et ses risques Annales de dermatologie 135, supplément 4, pp.249-253
DOI : 10.1016/s0151-9638(08)70543-x

B. Hansel and P. , Giral Prise en charge du syndrome métaboliques Sang thrombose vaisseaux 18, pp.539-547, 2006.

F. Illouz, P. Fressinaud, and P. H. , Ducluzeau Prise en charge thérapeutique du syndrome métabolique, pp.165-173, 2006.

F. Gasquet, S. Chartier, and J. P. Tcherny-lessenot, Lepine Etude schizophrenia outpatient health outcomes (SOHO) France : étude observationnelle à 36 mois d'une
DOI : 10.1016/j.respe.2008.11.001

M. De-hert, J. M. Dekker, D. Wood, D. G. Kahl, R. I. Holt et al., Möller Maladie cardiovasculaire et diabète chez les sujets souffrant d'une maladie mentale sévère. Déclaration de position de l'European Psychiatric Association (EPA), soutenue par l'European Association of the Study of Diabetes (EASD) et l

J. M. Meyer and H. A. , Nasrallah Medical Illness and schizophrenia, Medical comorbidity and access to quality medical care for patients with severe mental illness, pp.4-5, 2009.

F. Limosin, D. Gasquet, J. Leguay, and F. Mazorin, Rouillon Body mass index and prevalence of obesity in a french cohort patients with schizophrenia, Acta Psychiatrie Scand, vol.2008, pp.19-25

J. H. Thakore, J. N. Mann, I. Vlahos, A. Martin, and R. Resnek, Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia, International Journal of Obesity, vol.26, issue.1, pp.137-141
DOI : 10.1038/sj.ijo.0801840

J. E. Wildes, M. D. Marcus, and A. , Obesity in Patients With Bipolar Disorder, The Journal of Clinical Psychiatry, vol.67, issue.06, pp.904-915
DOI : 10.4088/JCP.v67n0607

P. Toalson, S. Ahmed, T. Hardy, and G. Kabinoff, The metabolic syndrome in patients with severe mental illness, J.Clin Psychiatry, issue.6, pp.152-158, 2004.

L. J. Williams, J. A. Pasco, M. J. Henry, F. N. Jacks, S. Dodd et al., Berk Life time psychiatric disorders and body composition : A population-based study, Journal of affective disorders, vol.2009, pp.173-179

R. I. Holt, R. C. Pevelert, C. D. Byrne, and . Schizophrenia, Schizophrenia, the metabolic syndrome and diabetes, Diabetic Medicine, vol.28, issue.6, pp.515-523
DOI : 10.1097/01.PSY.0000040951.22044.59

A. J. Scheen, B. Gillain, and M. , De Hert Maladie cardiovasculaire et diabète chez les personnes atteintes d'une maladie mentale sévère

S. Chabroux, E. Haffen, and A. , Penfornir Diabète et antipsychotiques de seconde génération Annales d'endocrinologie 70, pp.202-210
DOI : 10.1016/j.ando.2009.07.003

N. Lefebvre, I. Chereau, A. Schmitt, and P. M. , Llorca Comorbidités somatiques chez les patients souffrant de schizophrénie traitée
DOI : 10.1016/j.amp.2005.11.006

R. Pavlic, M. Zaliko, P. Filipovic, and T. , Car Hypertension and metabolic syndrome new trends in diagnosis monitoring ang management of metabolic syndrome, Acta Med Croatia, vol.59, issue.2005, pp.185-189

L. Johannessen, U. Strudsholm, L. Foldager, and P. , Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia, Journal of Affective Disorders, vol.95, issue.1-3, pp.13-17
DOI : 10.1016/j.jad.2006.03.027

B. I. Goldstein, A. Fagiolini, P. Houck, and D. J. , Kupfer Cardiovascular disease and hypertension among adults with bipolar disorder in the United States Bipolar disorders 11, pp.657-662

J. G. Fiedorowicz, N. M. Palagummi, V. L. Forman-hoffmann, D. D. Miller, and W. G. , Elevated Prevalence of Obesity, Metabolic Syndrome, and Cardiovascular Risk Factors in Bipolar Disorder, Annals of Clinical Psychiatry, vol.20, issue.3, pp.131-137
DOI : 10.1080/10401230802177722

J. Sicras, R. Relas, J. Navarro, and M. Serrat, Blanc Metabolic syndrome in bipolar disorder : across-sectional assessment of health management organization dates base Bipolar, pp.607-616

N. Y. Lee, S. H. Kim, B. Cho, Y. J. Lee, J. S. Schang et al., Ahn Patients taking medications for bipolar disorder are more prone to metabolic syndrome than korea's general population Progress in Neuro-psychopharmalogical 8 biological psychiatry 34, pp.1243-1249

A. P. John, R. Koloth, M. Dragovic, and S. C. Lim, Prevalence of metabolic syndrome among Australians with severe mental illness MJA 190, pp.176-179

J. M. Meyer and S. M. , Stahl The metabolic syndrome and schizophrenia Acta Psychiatrica Scandinavia 119, pp.4-14

M. Hasnain, S. K. Frederickson, W. V. Vieweg, and A. , Pandurangi Metabolic syndrome Associated with schizophrenia and atypical antipsychotics, Curr Diab Rep, vol.2010, pp.209-216
DOI : 10.1007/s11892-010-0112-8

D. Babic, B. Maslov, M. Martinac, K. Nikolic, S. Uzun et al., Kozymplik Bipolar Disorder and metabolic syndrome : comorbidity or side effects of treatment of bipolar disorder, Psychiatria Danubina, vol.22, issue.2010, pp.75-78

C. U. Cornell, A. M. Frederickson, J. M. Kane, and P. , Manu Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second generation Bipolar Desorders 10, pp.788-797, 2008.

C. H. Lin, Chen Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorders in Taïwan Acta Psychiatrica Scandinavia 120, pp.274-280

M. P. Garcia-portilla, P. A. Saiz, A. Benabarre, G. Florez, M. T. Bascaran et al., Bobes Impact of substance use on the physical health of patients with bipolar disorder Acta psychiatrica Scandinavia 121, pp.437-445

U. Zimmerman, T. Kraus, H. Himmerich, A. Schuld, and T. , Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients, Journal of Psychiatric Research, vol.37, issue.3, pp.193-220
DOI : 10.1016/S0022-3956(03)00018-9

O. Ruetsch, A. Viala, H. Bardou, P. Martin, M. N. Solida et al., Vacheron 57), Conus Syndrome métalobique et antipsychotiques atytpiques : recommandations et prise en charge clinique L'information psychiatrique, pp.715-724

M. Narasimhan, S. B. Bailey, and . Schizophrenia, Metabolic Syndrome and antipsychotics : challenges, controversies and clinical management Psychiatric times, pp.77-83, 2008.

J. Tschoner, M. Engl, S. Laimer, M. Kaser, W. W. Rettenbacher et al., Ebenbicher Metabolic side effects of antipsychotic medication, J. Clin Pract, vol.2007, issue.8, pp.61-1356

R. A. Davis, G. L. Rosenheck, J. Daumit, M. S. Hsiaro, T. S. Swartz et al., Lieberman Change in metabolic parameters with antipsychotic treatment in the CATIE schizophrenia trial : prospective date from phase 1

V. Simon, R. Van-winkel, and M. D. Hert, Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?, The Journal of Clinical Psychiatry, vol.70, issue.7, pp.1041-2009
DOI : 10.4088/JCP.08r04392

S. M. Stahl, L. Mignon, and J. M. , Meyer Which comes first : atypical antipsychotics treatment or cardiometabolic risk ? Acta Psychiatrica scandinavia 119, pp.171-179
DOI : 10.1111/j.1600-0447.2008.01334.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2008.01334.x/pdf

J. Flamand, Villeneuve Les perturbations métaboliques liées à la prise d'antipsychotiques de seconde génération l revue de littérature et prise en charge Pharmactuel, pp.91-101

G. P. Reynolds and S. L. , Metabolic side effects of antipsychotic drug treatment ??? pharmacological mechanisms, Pharmacology & Therapeutics, vol.125, issue.1, pp.169-179
DOI : 10.1016/j.pharmthera.2009.10.010

H. N. Boyda, L. Tse, R. M. Procyshym, W. G. Honer, and A. M. , Preclinical models of antipsychotic drug-induced metabolic side effects, Trends in Pharmacological Sciences, vol.31, issue.10, pp.484-497
DOI : 10.1016/j.tips.2010.07.002

J. W. Newcomer and D. W. , The Metabolic Effects of Antipsychotic Medications, The Canadian Journal of Psychiatry, vol.48, issue.8, pp.480-491
DOI : 10.1001/archpsyc.62.1.19

M. D. Llorente and V. , Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications, Clinical Diabetes, vol.24, issue.1, pp.18-24
DOI : 10.2337/diaclin.24.1.18

M. Gauthié, C. Golberger, J. P. Olié, H. Lôo, C. Gury et al., Poirier Evaluation des troubles métaboliques induits par les antipsychotiques atypiques chez les patients schizophrènes : L'Encéphale 31, pp.18-23

T. Lambert and L. , Chapman A consensus statement Diabetes, psychotic disorders ans antipsychotic therapy, pp.1-34, 2004.

A. and A. Naaso, Consensus Development Conference on antipsychotic drugs and obesity and diabetes Diabetes care, pp.596-601

D. Schizophrenia, Dubling, 3-4 october 2003 : consens summary The british journal of psychiatry 184, Expert Consensus Meeting, vol.2004, pp.112-114, 2003.

V. Woo, S. B. Harris, and R. L. , Houlden Canadian Diabètes Association Position paper : Antipsychotic medications and associeted risk of weight gain and diabetes, Canadian journal of diabetes, vol.29, issue.2005, pp.111-112

D. Nayer, M. D. Hert, A. Scheen, L. Van-gaal, and J. , Peuskens Troubles métaboliques associés aux antipsychotiques atypiques : consensus belge sur la conduite à tenir L'Encéphale, 33, pp.197-202, 2007.

M. D. Hert, D. Van-eyck, L. Hanssens, H. Peuskens, E. Thys et al., Peuskens Oral glucose tolerance test in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics ? European psychiatry 21, pp.224-226

T. A. Cohn and M. J. , Metabolic Monitoring for Patients Treated with Antipsychotic Medications, The Canadian Journal of Psychiatry, vol.280, issue.8, pp.492-501
DOI : 10.1001/jama.280.20.1757

B. L. Lambert, F. E. Cunnigham, D. R. Miller, G. W. Dalack, and K. Hur, Diabetes risk associated with use of olanzapine, quetiapine and risperidone in vettrans health administration patients with schizophrenia, Am J. Epidemiol, vol.2006, pp.164-672

H. Ascher-svanum, M. Stensland, Z. Zhao, and B. J. , Kinon Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia, BMC Psychiatry, vol.5, issue.2005, pp.1-13

D. J. Fagiolini, P. R. Kupfer, D. M. Houck, and E. Novick, Obesity as a Correlate of Outcome in Patients With Bipolar I Disorder, American Journal of Psychiatry, vol.160, issue.1, pp.112-117
DOI : 10.1176/appi.ajp.160.1.112

H. Buysse and D. J. Ombao, Kupfer Prevalence of obesity and weight change during treatment in patients with bipolar I disorder, J.Clin. Psychiatry, vol.63, issue.2002, pp.528-533

B. F. Tarricone, A. Gozzi, and D. Serrati, Weight gain in antipsychotic-naive patients: a review and meta-analysis, Psychological Medicine, vol.11, issue.02, pp.187-200
DOI : 10.4088/JCP.v68n0416

S. Saddichha, N. Manjunatha, S. Ameen, and S. , Abhtar Metabolic syndrome in first episode schizophrenia. A randomized double-blind controlled, short-term prospective study Schizophrenia research 101, pp.266-272

S. Saddichha, N. Manjunatha, and S. Ameen, Effect of olanzapine, risperidone and haloperidol ( treatment on weight and body mass index in first episode schizophrenia patients in India : a randomized doubleblind , controlles prospective study, J Clin Psychiatry, vol.68, issue.2007, pp.1793-1798

M. E. Shrivastava and . Johnston, Weight gain in psychiatric treatment : risks, implications, and strategies for prevention and management Psychopharmacology today, pp.53-68

C. U. Correll, A. M. Frederickson, J. M. Kane, and P. , Does antipsychotic polypharmacy increase the risk for metabolic syndrome?, Schizophrenia Research, vol.89, issue.1-3, pp.91-100
DOI : 10.1016/j.schres.2006.08.017

F. Misawa, K. Shimizy, Y. Fujii, R. Miyata, F. Koshiishi et al., Kashinoa Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustement for life-style effects : a cross-sectionnal study, BMC Psychiatry, vol.11, issue.2011, pp.1-8

R. Coccurello and A. , Moles Potential mechanisms of atypics antipsychotic-induced metabolic derangement : clues for unterstanding obesity and novel drug design Pharmacology 8 therapeutics 127, pp.210-251

E. J. Lowe and M. L. , Ackman Impact of tabacco smoking cessation on stable clozapine or olanzapine treatment The annals of pharmacotherapy, pp.727-732

M. Dobrinas, C. B. Eap, J. Cornuz, M. Kohler-serra, and M. , Puhl Aspects génétiques de la consommation de tabac et prise en charge clinique, Rev Med Suisse, vol.5, issue.2009, pp.1463-1467

R. Van-winkel, J. Van-os, I. Celic, D. Van-eyck, M. Wampers et al., Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances, The Journal of Clinical Psychiatry, vol.69, issue.8, pp.1319-1327
DOI : 10.4088/JCP.v69n0817

S. Gebhardt, M. Haberhausen, M. Heinzel-gutenbrunner, N. Gebhardt, H. Remschmidt et al., Theisen Antipsychotic-induced bodygain : predictors and a systematic categorization of the long-term weight course Journal of psychiatric research 43, pp.620-626

T. R. Barnes, C. Paton, M. R. Cavanagh, E. Hancock, and D. M. Taylor, on behaly of the UK prescribing observatory for mental health A UK audit of screening for the metabolic side effects of antipsychotics in community patients Schizophrénia bulletin, pp.33-1397

J. Kim, M. Nathanson, and V. A. Alsuwaidan, Taylor Bipolar disorder and metabolic syndrome : an international perspective, Journal of affective disorders, vol.126, issue.2010, pp.366-387

H. Jin, J. Meyer, S. Mudaliar, R. Henry, S. Khandrika et al., Use of Clinical Markers to Identify Metabolic Syndrome in Antipsychotic-Treated Patients, The Journal of Clinical Psychiatry, vol.71, issue.10, pp.1273-1278
DOI : 10.4088/JCP.09m05414yel

D. A. Weissman, C. S. Wirshing, L. Hall, X. Pogach, J. T. Pi-sunyer et al., Shon Physical Health Monitoring of patients with schizophrenia, AmJ Psychiatry, vol.161, issue.2004, pp.1334-1349

R. Gumber, M. Abbas, and M. , Minajagi Monitoring the metabolic side-effects of atypical antipsychotics The psychiatrist 34, pp.390-395

T. R. Barnes, C. Paton, E. Hancock, and P. , Lelliot, on behalf og the UK prescribing observatory for mental health Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics : a quality improvement programme Acta psychiatrica scandinavia 118, pp.26-33

I. R. Wiechers, M. Viron, J. Stoklosc, O. Freudenreich, D. C. Henderson et al., Weiss Impact of metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic, Academic psychiatry, vol.36, issue.2012, pp.118-121

C. E. Koro, D. O. Fedder, G. J. L-'italien, S. Weiss, L. S. Magder et al., Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study, BMJ, vol.325, issue.7358, pp.243-247
DOI : 10.1136/bmj.325.7358.243